Impact of elagolix treatment on fatigue experienced by women with moderate to severe pain associated with endometriosis

What Was Tested

The paper reports a study of Elagolix (non-peptide) in the context of endometriosis, published as a randomized controlled trial.

Who Took Part

According to the abstract, 860 women were involved.

The age groups tagged for this paper are teenagers, young adults, adults and middle-aged adults, women only.

A total of 860 women treated with elagolix or placebo.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and multicenter study.

Random assignment meant chance, not the researchers, decided who got Elagolix (non-peptide) and who got the comparison, which limits bias.

As a double-blind Elagolix (non-peptide) study, the assignments were hidden from both participants and investigators until the end.

Some women received a placebo instead of Elagolix (non-peptide), giving a reference point.

Running at several centres spread the Elagolix (non-peptide) study over different clinics and patient groups.

Randomized, double-blind, multicenter, placebo-controlled phase III trial.

What Was Measured

Topics PubMed links to this paper include Endometriosis, Fatigue, Gonadotropin-Releasing Hormone, Hormone Antagonists, Hydrocarbons, Fluorinated, Pain Measurement and Pelvic Pain.

Author keywords: elagolix and gonadotropin-releasing hormone antagonist.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Elagolix (non-peptide) in 860 women in people with endometriosis.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2019 (Fertility and sterility), a journal based in United States.

More context: the Elagolix (non-peptide) compound page, Endometriosis research.